SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP, a shareholder-rights law firm, announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).
The lawsuit, captioned Holtzman v. Beta Bionics, Inc., et al., No. 2:26-cv-09999, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.
To learn more and submit your information, visit:
https://www.johnsonfistel.com/investigations/beta-bionics-class-action/
What Is the Beta Bionics Class Action About?
Beta Bionics is a commercial-stage medical-device company that develops and commercializes diabetes-management products. Its sole commercialized product is the iLet Bionic Pancreas, an automated insulin-delivery system.
According to the complaint, defendants made materially false or misleading statements concerning the safety, efficacy, and commercial prospects of the iLet. After Beta Bionics disclosed that the U.S. Food and Drug Administration had issued a Form 483 following an inspection of the Company’s manufacturing facility, defendants allegedly assured investors that the FDA’s observations concerned only the Company’s criteria for determining which customer complaints were reportable, did not reflect an underlying problem with the device, and involved minor events that did not require medical intervention.
The complaint alleges that defendants failed to disclose that:
(1) the FDA had identified significant deficiencies involving Beta Bionics’ quality-management system, investigation and correction of known device malfunctions, and risk analysis for the iLet;
(2) customer complaints that Beta Bionics allegedly failed to investigate or timely report included serious injuries and potentially life-threatening hypoglycemic events requiring medical intervention;
(3) Beta Bionics allegedly had not implemented adequate corrective actions addressing known device malfunctions and safety risks; and
(4) as a result, defendants’ statements concerning the nature, scope, and likely remediation of the FDA’s concerns were materially false or misleading or lacked a reasonable basis.
The complaint further alleges that the truth emerged through a series of disclosures beginning on January 8, 2026 and culminating on February 24, 2026, when the FDA publicly released a warning letter detailing alleged violations and deficiencies.
What Is a Lead Plaintiff?
The lead plaintiff is a court-appointed investor who acts on behalf of the proposed class in directing the litigation. Investors seeking appointment as lead plaintiff must file their motions with the Court by November 3, 2026.
Serving as lead plaintiff is not required to share in any potential recovery. Investors may retain counsel of their choice, take no action, or remain absent members of the proposed class. No class has yet been certified.
Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. Frank J. Johnson is the attorney responsible for this communication.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations
(619) 814-4471
jimb@johnsonfistel.com
